Nanotrap® Particle Technology Platform
Infectious Disease Detection (e.g., Lyme, COVID-19)
Key Facts
About Ceres Nanosciences
Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.
View full company profileAbout Ceres Nanosciences
Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.
View full company profileAbout Ceres Nanosciences
Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.
View full company profileAbout Ceres Nanosciences
Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.
View full company profile